TLX Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$19.32 |
| 52 Week High | AU$20.76 |
| 52 Week Low | AU$8.20 |
| Beta | 2.45 |
| 11 Month Change | 2.17% |
| 3 Month Change | 29.58% |
| 1 Year Change | 71.73% |
| 33 Year Change | 243.16% |
| 5 Year Change | 1,154.55% |
| Change since IPO | 2,409.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 1.0% | -1.7% | -2.2% |
| 1Y | 71.7% | 14.8% | 5.4% |
Return vs Industry: TLX exceeded the Australian Biotechs industry which returned 14.8% over the past year.
Return vs Market: TLX exceeded the Australian Market which returned 5.4% over the past year.
Price Volatility
| TLX volatility | |
|---|---|
| TLX Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in AU Market | 16.4% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: TLX's share price has been volatile over the past 3 months.
Volatility Over Time: TLX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 423 | Chris Behrenbruch | telixpharma.com |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
Telix Pharmaceuticals Limited Fundamentals Summary
| TLX fundamental statistics | |
|---|---|
| Market cap | AU$6.47b |
| Earnings (TTM) | AU$31.68m |
| Revenue (TTM) | AU$576.27m |
204.1x
P/E Ratio11.2x
P/S RatioIs TLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLX income statement (TTM) | |
|---|---|
| Revenue | AU$576.27m |
| Cost of Revenue | AU$209.33m |
| Gross Profit | AU$366.95m |
| Other Expenses | AU$335.27m |
| Earnings | AU$31.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 0.095 |
| Gross Margin | 63.68% |
| Net Profit Margin | 5.50% |
| Debt/Equity Ratio | 6.1% |
How did TLX perform over the long term?
See historical performance and comparison